{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:10:21Z","timestamp":1778659821439,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["F.30-18\/2014-BSR"],"award-info":[{"award-number":["F.30-18\/2014-BSR"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Science and Technology, New Delhi, India","award":["SB\/YS\/LS100\/2014"],"award-info":[{"award-number":["SB\/YS\/LS100\/2014"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Science and Engineering: C"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.msec.2016.11.122","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T21:03:09Z","timestamp":1480712589000},"page":"611-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations"],"prefix":"10.1016","volume":"72","author":[{"given":"Sonam","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Gothwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iliyas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msec.2016.11.122_bb0005","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.msec.2016.11.122_bb0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.msec.2016.11.122_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.msec.2016.11.122_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1,027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.msec.2016.11.122_bb0025","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.msec.2016.11.122_bb0030","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.msec.2016.11.122_bb0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.msec.2016.11.122_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msec.2016.11.122_bb0045","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.msec.2016.11.122_bb0050","unstructured":"B.G.M. Durie, International Myeloma Foundation, 2011\/2012 edition."},{"key":"10.1016\/j.msec.2016.11.122_bb0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.msec.2016.11.122_bb0060","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.msec.2016.11.122_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.msec.2016.11.122_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.msec.2016.11.122_bb0075","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.msec.2016.11.122_bb0080","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/j.1751-553X.2009.01145.x","article-title":"The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562\/A02","volume":"32","author":"L\u00fc","year":"2010","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.msec.2016.11.122_bb0085","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1078155210386268","article-title":"Stability of unused reconstituted bortezomib in original manufacturer vials","volume":"17","author":"Vanderloo","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.msec.2016.11.122_bb0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2217\/nnm.10.27","article-title":"Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation","volume":"5","author":"Wei","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.msec.2016.11.122_bb0095","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.msec.2016.11.122_bb0100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biomaterials.2013.09.098","article-title":"The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy","volume":"35","author":"Shen","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.msec.2016.11.122_bb0105","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1248\/cpb.c16-00035","article-title":"Formulation and evaluation of a self-microemulsifying drug delivery system containing bortezomib","volume":"64","author":"Hong","year":"2016","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.msec.2016.11.122_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2014.12.043","article-title":"Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy","volume":"208","author":"Shen","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.msec.2016.11.122_bb0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-3659(03)00200-1","article-title":"Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin","volume":"90","author":"Chauhan","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.msec.2016.11.122_bb0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1021\/la010859+","article-title":"Study of poly(propylene imine) dendrimers in water, by exciplex formation","volume":"18","author":"Pistolis","year":"2002","journal-title":"Langmuir"},{"key":"10.1016\/j.msec.2016.11.122_bb0130","series-title":"Controller of Publication","author":"Pharmacopoeia of India","year":"1996"},{"key":"10.1016\/j.msec.2016.11.122_bb0135","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/anie.199313081","article-title":"Poly (propylene imine) dendrimers: large scale synthesis by heterogenously catalyzed hydrogenation","volume":"32","author":"Brabander-van den Berg","year":"1993","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.msec.2016.11.122_bb0140","first-page":"358","article-title":"Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes","volume":"10","author":"Gupta","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.msec.2016.11.122_bb0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2010.04.002","article-title":"Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells","volume":"393","author":"Gupta","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2016.11.122_bb0150","series-title":"Advances in Analytical Chemistry and Instrumentation","first-page":"117","article-title":"Phase-solubility techniques","author":"Higuchi","year":"1965"},{"key":"10.1016\/j.msec.2016.11.122_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2007.05.039","article-title":"Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complex","volume":"345","author":"Devarakonda","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2016.11.122_bb0160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/jf0111965","article-title":"Study on the supramolecular interaction of curcumin and cyclodextrin by spectrophotometry and its analytical application","volume":"50","author":"Tang","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.msec.2016.11.122_bb0165","unstructured":"Protein Preparation Wizard, Impact, Desmond, Lig Prep, Maestro, Schr\u00f6dinger, LLC, USA, (2015) 1."},{"key":"10.1016\/j.msec.2016.11.122_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijpharm.2005.07.023","article-title":"Comparision of aqueous solubilization of practically insoluble niclosamide by polyamidoamone (PAMAM) dendrimers and cyclodextrins","volume":"300","author":"Devarakonda","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2016.11.122_bb0175","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.ejmech.2005.08.002","article-title":"Polyamidoamine dendrimers used as solubility enhancers of ketoprofen","volume":"40","author":"Yiyun","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.msec.2016.11.122_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5173(01)00901-2","article-title":"Effect of dendrimer on entrapment and release of bioactive from liposomes","volume":"232","author":"Khopade","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2016.11.122_bb0185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jconrel.2003.12.006","article-title":"The use of a dendrimer propranolol prodrug to bypass efflux transporters and enhance oral bioavailability","volume":"95","author":"D'Emanuele","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.msec.2016.11.122_bb0190","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1208\/pt060367","article-title":"(PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient","volume":"6","author":"Asthana","year":"2005","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.msec.2016.11.122_bb0195","first-page":"1","article-title":"The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil","volume":"8","author":"Erturk","year":"2016","journal-title":"Pharm. Dev. Tech."},{"key":"10.1016\/j.msec.2016.11.122_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5173(99)00463-9","article-title":"Polyamidoamine starburst dendrimers as solubility enhancers","volume":"197","author":"Milhem","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.msec.2016.11.122_bb0205","series-title":"Physical Pharmacy","article-title":"Thermodynamics","author":"Martin","year":"1999"}],"container-title":["Materials Science and Engineering: C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493116318562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493116318562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T07:21:07Z","timestamp":1536218467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928493116318562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":40,"alternative-id":["S0928493116318562"],"URL":"https:\/\/doi.org\/10.1016\/j.msec.2016.11.122","relation":{},"ISSN":["0928-4931"],"issn-type":[{"value":"0928-4931","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypropyleneimine and polyamidoamine dendrimer mediated enhanced solubilization of bortezomib: Comparison and evaluation of mechanistic aspects by thermodynamics and molecular simulations","name":"articletitle","label":"Article Title"},{"value":"Materials Science and Engineering: C","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msec.2016.11.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}